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Background: Esophageal varices (EV) are a complication of cystic fibrosis-associated liver disease. Esophagogastroduodenoscopy (EGD) is
currently used to diagnose varices but is invasive for pediatric patients. The goal of this study was to explore the relationship between transient
elastography (FibroScan®) and the presence of EV in patients with liver disease defined by clinical, laboratory, sonographic, and/or endoscopic
criteria.
Methods: 18 patients with cystic fibrosis underwent EGD and transient elastography. 12 patients had EV.
Results: Patients with EV had higher FibroScan values than those without varices with median values of 22.4 kPa (14.4-30.4 kPa) vs. 7.9 kPa
(4.4-13.7 kPa) (p=0.01). Using a threshold of 12 kPa, four of six patients without EV would not have needed EGD.
Conclusions: Elastography should be recommended for all cystic fibrosis patients with liver disease to follow its progression. A prospective study
is needed to define an elastography threshold value that predicts the presence of EV.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Approximately 3000 children in France under 18 years of
age have cystic fibrosis (CF) [1]. Liver disease, the third most
common cause of death in CF patients following cardiopulmo-
nary and post-transplantation complications [2,3], is character-
ized by bile duct obstruction from biliary hyperviscosity, which⁎ Corresponding author at: Department of Pediatrics, Center for Cystic
Fibrosis Resources and Expertise, Medical Center, boulevard Laennec 44600
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doi:10.1016/j.jcf.2011.04.004leads to focal cirrhosis followed by multilobular biliary
cirrhosis. This condition can be complicated by portal
hypertension and esophageal or gastric varices. Ursodeoxy-
cholic acid (UDCA) is currently the only available treatment
and may facilitate the stabilization or regression of liver lesions
[4]. The successful management of portal hypertension includes
early detection of esophageal varices and their hemorrhagic
complications.
Although liver abnormalities are often present near the end
of the first 10 years, diagnosis is frequently delayed due to the
subclinical nature of early symptoms. The current means used to
detect liver disease and its complications are inadequate [5,6].d by Elsevier B.V. All rights reserved.
Table 1
Clinical, laboratory, and sonographic data. Results are expressed as the medians
(25th–75th percentiles) *=p=0.003 nonparametricWilcoxon test. EV+=esophageal
varices present; EV−=esophageal varices absent. Platelet counts were significantly
elevated in patients with esophageal varices.
All (n=18) EV+ (n=12) EV− (n=6)
Age 14 (11.5–15) 13.5 (11–14.5) 14.5 (13.3–15)
Meconium ileus 4 3 1
Clinical hepatomegaly 15 12 3
Clinical splenomegaly 13 12 1
Albumin (g/l) 41.8
(39.9–42.7)
40.9
(39.5–42)
41.9
(41.8–43)
PT (%) 82 (70–94) 77 (63–97) 85 (82–87)
Platelets (×1000/mm3) 151 (72–232) 91.5 (65.7–144)* 257 (234–310)*
Normal ultrasound 0 0 0
Sonographic hepatomegaly 16 12 4
▪ Normal parenchyma 1 0 1
▪ Heterogeneous
parenchyma
3 2 1
▪ Nodular liver 10 7 3
▪ Associated steatosis 4 4 0
No sonographic
hepatomegaly
2 0 2
▪ Nodular liver 2 0 2
▪ Steatosi 1 0 1
Sonographic
splenomegaly
12 11 1
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megaly), and the available laboratory markers (gamma glutamyl
transferase or transaminases) lack sensitivity and specificity.
Although ultrasound may identify nodules, hepatomegaly, and
splenomegaly, this method presents an interobserver variability
and lacks sensitivity. Liver biopsy is invasive and may not be
diagnostic due to the focal nature of liver disease; therefore, it is
rarely performed in children [6]. There are no recommendations
regarding endoscopy for the detection of asymptomatic
esophageal varices for the management of cystic fibrosis [7].
Although invasive, early endoscopy is performed by several
groups to better anticipate hemorrhagic complications.
New, noninvasive, sensitive, and specific techniques have
been developed to improve the detection of hepatic fibrosis in
chronic liver disease. Transient elastography is a noninvasive
technique that uses ultrasound to quantify liver stiffness, a
variable that is correlated with fibrosis. Transient elastography
has been used for several years in adults with chronic liver
disease to detect cirrhosis and to evaluate the complications of
portal hypertension [8,9]. In adults and in children [10–13],
transient elastography is being evaluated for cystic fibrosis-
associated liver disease and for the detection of esophageal
varices in other causes of cirrhosis in children [14]. The goal of
this study was to investigate the relationship between transient
elastography values and the presence of esophageal varices in
CF patients with liver disease.
2. Patients and methods
The study was an open, multicenter, retrospective review.
We included cystic fibrosis patients 18 years of age or younger
with liver disease who had undergone esophagogastroduodeno-
scopy (EGD) for detection of esophageal varices (children
being examined for another reason (gastroesophageal reflux or
other indication) were excluded) and transient elastography
within a 12-month window.
Liver disease was defined by the presence of at least two of
the following conditions: clinical hepatomegaly; hepatomegaly
without steatosis, heterogeneous or nodular liver parenchyma
on ultrasound; clinical, laboratory, or sonographic signs of
portal hypertension, including defined splenomegaly, a platelet
count of less than 150,000/mm3, or esophageal varices or other
signs of portal hypertension on an EGD.
Liver biochemistry tests (Gama glutamyl transferase and
transaminases) are known for very low sensitivity and were not
taken in account [5].
Clinical findings, laboratory analyses (platelet count,
prothrombin time and serum albumin) and abdominal ultra-
sound results (hepatomegaly, liver heterogeneity, and hepatic
nodules) were recorded during a 6-month window before and
after the EGD and transient elastography.
For each EGD, we recorded the patient age at the time of the
examination, the presence or absence of esophageal varices, the
grade of esophageal varices, the presence of other signs of portal
hypertension (gastric varices or portal hypertensive gastropathy)
or other abnormalities (esophagitis). The patients were divided
into two groups, based on the presence or absence of esophagealvarices. Patients who underwent prior endoscopic treatment for
esophageal varices (sclerotherapy or ligation) were excluded.
Hepatic fibrosis by transient elastography was evaluated
using the same FibroScan® (Echosens, Paris, France) device in
all centers. Measurements were performed in the right hepatic
lobe through an intercostal space with the patient in a dorsal
decubitus position, with the right arm in maximal abduction.
After applying sonographic gel to the patient's skin, the
operator located the liver by ultrasound using the FibroScan
probe. Measurements were not modified according prior
detection of nodular areas by ultrasound. All patients were
examined with the medium probe (M) since they all had a
thoracic circumference more than 75 cm. Once the appropriate
zone was identified, the medium probe performed measure-
ments between 25 and 65 mm of depth. The final result is the
median of 10 valid measurements, which represents the liver
stiffness. FibroScan values are reported in kilopascals (kPa). To
be valid, the FibroScan values must meet two conditions: the
success rate, defined as the number of valid measurements
divided by the total number of measurements performed, must
be greater than or equal to 60%; and the Interquartile Range
(IQR), which takes into account the variability of valid
measurements, must be less than 30% of the median.
Results are given as the median, 25th percentile, and 75th
percentile.
Nonparametric Wilcoxon tests were performed to compare
the quantitative values. The Spearman's rank correlation was
used to evaluate the correlation between the quantitative values.
The threshold for significance was 0.05 (pb0.05) with a 95%
confidence interval.
Table 2
Results of the transient elastography. * nonparametric Wilcoxon test ns=not
significant Results are expressed as the medians (25th–75th percentiles).
EV+=esophageal varices present; EV−=esophageal varices absent. FibroScan
values were significantly elevated in patients with esophageal varices.
All (n=18) EV+ (n=12) EV− (n=6) p
Age (years) 14 (11.5–15) 13.5 (11–14.5) 14.5 (13.3–15) ns
FibroScan (kPa) 16.4 (12.2–23.7) 22.4 (14.4–30.4) 7.9 (4.4–13.7) 0.01*
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Demographics: 18 children, 11 male and 7 female, from 9 to
18 years, were included. Half of the children were homozygous
carriers of the Delta F508 mutation, one-third were heterozy-
gous for the Delta F508 mutation, and the remaining three
carried two non-Delta F508 mutations. Only one patient did not
receive UDCA therapy; this child had isolated hepatomegaly
with normal parenchyma, without fatty infiltration (steatosis) on
ultrasonography and presented a clinical hepatomegaly without
other clinical or laboratory abnormalities. Four children (22%),
including three females, presented with neonatal meconium
ileus.
All patients had undergone EGD and valid transient
elastography between July 2005 and February 2010, and the
two tests were separated by less than 1 year (median 3 months,
ranging 1–5 months). The median age at the time of transient
elastography was 14 years (11.5–15).
The clinical, laboratory, and sonographic data are given in
Table 1. Fifteen patients had clinically apparent hepatomegaly,
and 13 had clinically apparent splenomegaly. A single patient
presented with collateral venous circulation and spider
hemangiomas. None of the patients had jaundice or ascites or
presented with gastrointestinal hemorrhage. A total of 14
children presented with portal hypertension, which was defined
by clinical criteria (splenomegaly) in 13, laboratory criteria
(plateletsb150,000/mm3) in 9, and sonographic criteria
(splenomegaly) in 13. The presence of esophageal varices was
associated with significantly lower platelet counts (p=0.003).
No significant differences were identified for the other values0
20
40
60
80
EV -
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Fig. 1. Distribution of transient elastography values in patients with or without
esophageal varices. Results are expressed in kilopascals (kPa). EV grade
I=esophageal varices grade I present; EV grade II=esophageal varices grade II
present; EV grade III=esophageal varices grade III present; EV−=esophageal
varices absent. FibroScan values in patients with or without esophageal varices
overlap between 12 and 18 kPa but are significantly elevated in patients with
esophageal varices.recorded. Ultrasound was most frequently performed on the
same day as the EGD or transient elastography or within
6 months of these studies. All of the patients had sonographic
abnormalities. Sixteen patients had hepatomegaly, and 12 had
cirrhosis, as evidenced by a nodular liver. All of the patients
with esophageal varices had hepatomegaly, and all but one had
splenomegaly. The one exception had a heterogeneous liver
with grade II esophageal varices and petechial duodenitis on
the EGD.
As an inclusion criterion, all patients underwent both EGD
and transient elastography. Esophageal varices were present in
12 patients. There were six patients with grade I varices
(associated with gastric varices in one, with peptic esophagitis
in one, and with portal hypertensive gastropathy in two); five
patients had grade II varices (associated with duodenitis in one),
and one patient had grade III varices. One child presented
gastropathy without varices. Five patients had normal EGDs.
The results of the 18 FibroScan evaluations are given in
Table 2. The measurements ranged from 3 to 75 kPa with a
median of 16.4 kPa (12.2–23.7 kPa). FibroScan values in
patients with esophageal varices were significantly elevated
(p=0.01; nonparametric Wilcoxon test). Individual results are
given for both groups in Fig. 1 and demonstrate overlap. The
lowest value among the 12 patients with esophageal varices was
12 kPa. The highest value among the six patients without
varices was 17.5 kPa, and four had FibroScan values lower than
the threshold of 12 kPa. FibroScan values in patients with no or
grade I varices were not significantly different from those in
patients with grade II–III varices and red spots.
There was a negative correlation between the patients'
platelet counts and liver stiffness (p=0.0005; Spearman's rank
correlation).
4. Discussion
The age at presentation, the rate of progression, and the
severity of liver disease in cystic fibrosis patients are variable.
The prevalence of liver disease increases with age and affects
10% of children [5] and 72% of adults. Most patients present
with liver abnormalities at or before the onset of puberty [2].
The latest data from the French National Cystic Fibrosis
Observatory revealed liver abnormalities in relatively young
patients, with 5.3% of children diagnosed with cirrhosis and/or
portal hypertension between the ages of 10 and 14 [1].
Liver disease is frequently diagnosed only after the appear-
ance of complications related to cirrhosis and portal hyperten-
sion. The treatment for esophageal varices is endoscopic ligation
after the bleeding risk becomes elevated. Although there is
controversy, current knowledge supports prophylactic treatment
for grade II esophageal varices with “cherry red spots” [15–18].
There is currently no noninvasive test with sufficient sen-
sitivity or specificity to predict the development of esophageal
varices after cirrhosis has been diagnosed. Endoscopic surveil-
lance remains the gold standard. There are no recommendations
regarding endoscopy for the detection of esophageal varices prior
to the development of hemorrhage for the management of cystic
fibrosis [7]. Several groups perform early endoscopy to better
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could be a prophylactic ligation of varices, which has been
increasingly recommended in adults [15,16,18] and childrenwith
other causes of portal hypertension like biliary atresia [17].
However, in CF, for children with diminished pulmonary
function, endoscopy and the requirement for sedation or general
anesthesia carry extra risks. It is therefore necessary to find a
noninvasive, sensitive, and specific test that can stratify patients
based on risk and potentially be used to predict the grade of
varices, and even hemorrhagic risk.
In our study, low platelet count is significantly correlated
to presence of EV, this complication being due to portal
hypertension. Nevertheless, low platelet count can't be solely
attributed to portal hypertension. It is commonly due to splenic
sequestration but reduced levels of thrombopoietin may also be
implicated [19]. The use of FibroScan for the diagnosis of
fibrosis or cirrhosis has been evaluated in children with multiple
hepatic pathologies [10] and in non-alcoholic steatohepatitis
[20]. These studies have shown that FibroScan may be used in
children and that it correlates with the METAVIR score
established by liver biopsy. De Ledinghen et al. analyzed
FibroScan values in multiple pediatric chronic liver diseases,
including 42 CF patients [10], and found that the FibroScan
values correlated with the fibrosis score from liver biopsies in
children. E Breton et al. [11] also evaluated FibroScan in a study
of 72 patients aged 4 to 18 years, including 20 patients with CF.
The patients with liver disease (defined by clinical, sonograph-
ic, or laboratory criteria) had significantly elevated FibroScan
values. B Ganucheau et al. [21] demonstrated that FibroScan
values correlated with liver disease in 70 children with CF. In
2010, Menten et al. [12] studied FibroScan measurements in
134 CF patients and found that the FibroScan values were
significantly elevated in patients with sonographic evidence of
fibrosis. Witters et al. found a significant elevation in the
FibroScan values of 66 CF patients with liver disease, as
defined by clinical, laboratory, or sonographic markers [13].
In adults, FibroScan has been approved and recommended by
the High Health Authority for the detection of hepatic fibrosis in
hepatitis C, co-infected patients with HCV and HIV. Transient
elastography produced excellent results in the diagnosis of
cirrhosis in adults in multiple studies with various thresholds that
depended on the study and cause of the liver disease [8,9,22–24].
In children, no FibroScan threshold has been defined for the
diagnosis of cirrhosis or its complications. Among the 72
children studied by Breton et al. [11], nine patients with portal
hypertension (diagnosed by liver biopsy, clinical, laboratory,
and/or sonographic evaluation) had liver stiffness values that
were significantly elevated compared to those without portal
hypertension. In a preceding study [21], among 70 CF patients
aged 6 to 20 years, 14 had portal hypertension and 7 had
FibroScan values above 14.6 kPa. The presence of portal
hypertension as defined by clinical, laboratory, or sonographic
criteria was associated with a significantly elevated liver stiffness
value. Platelet counts and FibroScan values were inversely
correlated. In our study, the FibroScan values were significantly
elevated in patients with esophageal varices. Multiple studies
have sought to define a FibroScan threshold that would permit theprediction of esophageal varices in adult patients with cirrhosis,
which would improve the prediction of hemorrhagic risk and
avoid performing endoscopy too early. Foucher et al. [9] reported
that a threshold of 27.5 kPa had a 90% negative predictive value
for the presence of grade II or III esophageal varices in various
chronic adult liver diseases. This threshold varied between
studies and ranged from 19 kPa [25] to 47.2 kPa [22] with good
sensitivities and specificities. In 2009, a Korean group [14]
studied the correlation between FibroScan scores and the
appearance of esophageal varices in 49 children following the
Kasai procedure for biliary atresia. The FibroScan values were
significantly elevated in children with portal hypertension, with a
threshold for the prediction of esophageal or gastric varices of
9.7 kPa, which yielded 97% sensitivity and 80% specificity [14].
In the setting of CF, the goal would be to define a threshold value
above which there is a high probability of esophageal varices to
prevent unnecessary and potentially risky endoscopies. Our
study is not sufficiently powerful to formally validate a threshold
that is predictive of esophageal varices, with an overlap of values
between 12 and 18 kPa in patients with and without varices. The
overlap of liver stiffness could be secondary to sampling errors,
due to steatosis or heterogeneity of liver disease while the
sampling volume of transient elastography is bigger than that of
liver biopsy [23].
Among the children without esophageal varices, four had a
FibroScan value below the 12 kPa threshold, which was the
lowest value seen in a patient with varices. Four endoscopies
would have been averted using this threshold. Our results should
be validated by a higher powered, multicenter, prospective trial.5. Conclusion
The detection of liver disease in cystic fibrosis, including early
fibrosis, cirrhosis, and the development of portal hypertension and
its complications, remains a challenge and is an issue of debate.
EGD remains the gold standard for detecting esophageal varices.
Transient elastography is a non-invasive method that does not
replace endoscopy but may be useful for targeting EGD and
improving overall patient management. FibroScan values corre-
lated with the presence of esophageal varices and were inversely
related to platelet count. Transient elastography should be
regularly used for cystic fibrosis patients with clinical, laboratory,
or sonographic abnormalities suggestive of liver disease, which
will facilitate the eventual determination of a threshold for the
recommendation of EGD. FibroScan values could eventually be
combined with platelet count. These results need to be confirmed
with a prospective study.References
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